Telix Reports the First Patient Dosing of TLX101 in P-I Study (IPAX-2) for Newly Diagnosed Glioblastoma
Shots:
- The first patient has been dosed in a P-I dose escalation study (IPAX-2) evaluating the safety profile of TLX101 (4-L-[131I] iodophenylalanine or 131I-IPA) + external beam radiation therapy & temozolomide at 6 sites across Australia, New Zealand & EU. The study is expected to be enrolled 12 patients
- The (IPAX-1) study met its primary objective demonstrating the safety & tolerability profile of IV, 131I-IPA administered with 2L EBRT & also showed an encouraging preliminary therapeutic effect with a m-OS of 13mos. from the initiation of treatment in the recurring setting, or 23mos. from initial diagnosis
- TLX101 is being studied in the recurrent setting in the investigator-initiated P-II study (IPAX-Linz). The therapy received ODD in the US & EU for glioblastoma
Ref: PRNewswire | Image: Telix Pharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
